Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C12H15NO3S |
| Molecular Weight | 253.317 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CNC(=O)C(CS)CC1=CC=CC=C1
InChI
InChIKey=LJJKNPQAGWVLDQ-UHFFFAOYSA-N
InChI=1S/C12H15NO3S/c14-11(15)7-13-12(16)10(8-17)6-9-4-2-1-3-5-9/h1-5,10,17H,6-8H2,(H,13,16)(H,14,15)
| Molecular Formula | C12H15NO3S |
| Molecular Weight | 253.317 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Thiorphan is the first potent synthetic inhibitor of enkephalinase. Thiorphan displays antinociceptive activity after systemic administration. Thiorphan also inhibits to a lesser extent the widely distributed angiotensin-converting enzyme, a carboxydipeptidase implicated in blood pressure regulation. Thiorphan failed to potentiate allergen-induced airway responses in asthma. Thiorphan significantly reduced the castor oil-induced diarrhea in rats when administered intravenously but not when administered intracerebroventricularly. Racecadotril, via its active metabolite thiorphan, was consistently effective in animal models and patients with various forms of acute diarrhea by inhibiting pathologic (but not basal) secretion from the gut without changing gastro-intestinal transit time or motility.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3479550https://www.ncbi.nlm.nih.gov/pubmed/22661949
Curator's Comment: Ecadotril ((S)-acetorphan) is CNS active in animals when administered parenterally. No human data available.
Originator
Sources: http://adisinsight.springer.com/drugs/800001163https://www.ncbi.nlm.nih.gov/pubmed/7001254
Curator's Comment: Roques, B. P., Schwartz, J. C. & Lecomte, J. M., inventors. Derives d'acides amines et leur application therapeutique. Fr. Pat. 8008601, Apr. 17, 1980; Eur. Pat. Appl. EP 38,758; Apr. 14, 1981.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2994 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3479550 |
|||
Target ID: CHEMBL2642 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3479550 |
|||
Target ID: CHEMBL2642 |
3.5 nM [Ki] | ||
Target ID: CHEMBL2994 |
140.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22661949 |
Primary | Unknown Approved UseUnknown |
||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8872633 |
Palliative | Unknown Approved UseUnknown |
||
| Primary | Unknown Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Dizziness, Headache... Other AEs: Dizziness (grade 1-2, 35%) Sources: Headache (16%) Insomnia (6%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Headache | 16% | 400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Insomnia | 6% | 400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Dizziness | grade 1-2, 35% | 400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| inconclusive [Activation 11.2202 uM] | ||||
| no | ||||
| no | ||||
| yes [IC50 0.1259 uM] | ||||
| yes [IC50 0.3162 uM] | ||||
| yes [IC50 0.6918 uM] | ||||
| yes [IC50 1.2302 uM] | ||||
| yes [IC50 2.512 uM] |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril. | 2012 |
|
| Role of mu- and delta-opioid receptors in the nucleus accumbens in cocaine-seeking behavior. | 2009-07 |
|
| Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. | 2008-10-15 |
|
| Thiorphan, a neutral endopeptidase inhibitor used for diarrhoea, is neuroprotective in newborn mice. | 2006-12 |
|
| Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis. | 2006-02 |
|
| Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. | 2005-12 |
|
| Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: a new target to treat portal hypertension? | 2005-11 |
|
| The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat. | 2004-06 |
|
| Strategies for access to enantiomerically pure ecadotril, dexecadotril and fasidotril: a review. | 2002-06 |
|
| Effects of chronic neutral endopeptidase inhibition on the progression of left ventricular dysfunction and remodeling in dogs with moderate heart failure. | 2002-05 |
|
| Perceived benefit after participating in positive or negative/neutral heart failure trials: the patients' perspective. | 2001-03 |
|
| Ecadotril. (S)-acetorphan, sinorphan. | 1999-04 |
|
| Inhibition of opioid-degrading enzymes potentiates delta9-tetrahydrocannabinol-induced antinociception in mice. | 1998 |
|
| Role of neutral endopeptidase in exercise-induced bronchoconstriction in asthmatic subjects. | 1996-08 |
|
| The effect of inhaled thiorphan on allergen-induced airway responses in asthmatic subjects. | 1996-05 |
|
| Attenuation of the morphine withdrawal syndrome by inhibition of catabolism of endogenous enkephalins in the periaqueductal gray matter. | 1992-04 |
|
| Naloxone-reversible antidiarrheal effects of enkephalinase inhibitors. | 1987-12-01 |
|
| Pharmacological properties of acetorphan, a parenterally active "enkephalinase" inhibitor. | 1986-06 |
|
| Complete differentiation between enkephalinase and angiotensin-converting enzyme inhibition by retro-thiorphan. | 1983-06 |
|
| Thiorphan potentiation of stress-induced analgesia in the mouse. | 1982-09-20 |
|
| The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. | 1980-11-20 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:00:42 GMT 2025
by
admin
on
Mon Mar 31 21:00:42 GMT 2025
|
| Record UNII |
B79L7B5X3Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
727676
Created by
admin on Mon Mar 31 21:00:42 GMT 2025 , Edited by admin on Mon Mar 31 21:00:42 GMT 2025
|
PRIMARY | |||
|
DTXSID70868412
Created by
admin on Mon Mar 31 21:00:42 GMT 2025 , Edited by admin on Mon Mar 31 21:00:42 GMT 2025
|
PRIMARY | |||
|
76721-89-6
Created by
admin on Mon Mar 31 21:00:42 GMT 2025 , Edited by admin on Mon Mar 31 21:00:42 GMT 2025
|
PRIMARY | |||
|
100000085216
Created by
admin on Mon Mar 31 21:00:42 GMT 2025 , Edited by admin on Mon Mar 31 21:00:42 GMT 2025
|
PRIMARY | |||
|
D015244
Created by
admin on Mon Mar 31 21:00:42 GMT 2025 , Edited by admin on Mon Mar 31 21:00:42 GMT 2025
|
PRIMARY | |||
|
SUB21843
Created by
admin on Mon Mar 31 21:00:42 GMT 2025 , Edited by admin on Mon Mar 31 21:00:42 GMT 2025
|
PRIMARY | |||
|
B79L7B5X3Z
Created by
admin on Mon Mar 31 21:00:42 GMT 2025 , Edited by admin on Mon Mar 31 21:00:42 GMT 2025
|
PRIMARY | |||
|
DB08626
Created by
admin on Mon Mar 31 21:00:42 GMT 2025 , Edited by admin on Mon Mar 31 21:00:42 GMT 2025
|
PRIMARY | |||
|
THIORPHAN
Created by
admin on Mon Mar 31 21:00:42 GMT 2025 , Edited by admin on Mon Mar 31 21:00:42 GMT 2025
|
PRIMARY | |||
|
3132
Created by
admin on Mon Mar 31 21:00:42 GMT 2025 , Edited by admin on Mon Mar 31 21:00:42 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE |
|
||
|
|
ENANTIOMER -> RACEMATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
bulk of its inhibitory actions on enkephalinase.
MAJOR
PLASMA
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> IMPURITY |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|